Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VSF1.01 + human umbilical cord mesenchymal stem cell-derived extracellular vesicles
- Development stage
- Unknown
- Lead developer
- Medizinische Hochschule Hannover
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Intratympanic
01
Overview
VSF1.01 + human umbilical cord mesenchymal stem cell-derived extracellular vesicles is a combination regenerative therapy developed by the Hannover Medical School (Medizinische Hochschule Hannover, MHH) for the treatment of sensorineural hearing loss. The product consists of extracellular vesicles (EVs) harvested from human umbilical cord mesenchymal stem cells (hUC-MSCs) encapsulated within a specialized thermoreversible poloxamer-based hydrogel delivery system designated as VSF1.01. The hUC-MSC-EVs function as a biologic cargo containing a complex mixture of proteins, microRNAs, and lipids that exert neuroprotective, anti-inflammatory, and anti-apoptotic effects on damaged cochlear hair cells and spiral ganglion neurons. The VSF1.01 gel is designed to be liquid at room temperature for easy intratympanic injection and solidifies into a depot at body temperature upon contact with the middle ear mucosa. This allows for the sustained release and diffusion of the vesicles through the round window membrane into the inner ear, overcoming the rapid clearance typically associated with liquid formulations.
- Other names
- hUC-MSC-EVs in VSF1.01MSC-EV gelhuman umbilical cord mesenchymal stem cell-derived extracellular vesicles in thermoreversible gel
Beyond the preview
Go deeper on VSF1.01 + human umbilical cord mesenchymal stem cell-derived extracellular vesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VSF1.01 + human umbilical cord mesenchymal stem cell-derived extracellular vesicles.